Last reviewed · How we verify

NCT03000075

BI 655066 (Risankizumab) Compared to Placebo in Japanese Patients With Moderate to Severe Chronic Plaque Psoriasis

Completed Phase 2 Results posted Last updated 21 May 2019
What this trial tests

Phase 2 trial testing risankizumab in Psoriasis in 182 participants. Completed in 20 June 2018.

Timeline
2 December 2016
Primary endpoint
21 September 2017
20 June 2018

Quick facts

Lead sponsorAbbVie
PhasePhase 2
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingdouble
Primary purposetreatment
Enrollment182
Start date2 December 2016
Primary completion21 September 2017
Estimated completion20 June 2018

Drugs / interventions tested

Conditions studied

Sponsor

AbbVie — full company profile →

Who can join

20 and older, any sex, with Psoriasis. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Percentage of Participants Achieving 90% Improvement in Psoriasis Area and Severity Index (PASI) Score (PASI90) at Week 16 (Part A) Primary · Week 16

PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign was assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis. PASI90 is defined as at least a 90% reduction in PASI score compared with the Baseline PASI score. The percent

GroupValue95% CI
Placebo (Part A)1.7
Risankizumab 75 mg (Part A)75.9
Risankizumab 150 mg (Part A)74.5
Percentage of Participants Achieving PASI90 at Week 52 (Part B) Secondary · Week 52

PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign was assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis. PASI90 is defined as at least a 90% reduction in PASI score compared with the Baseline PASI score. The percent

GroupValue95% CI
Placebo/Risankizumab 75 mg (Part B)81.5
Placebo/Risankizumab 150 mg (Part B)85.2
Risankizumab 75 mg/Risankizumab 75 mg (Part B)86.2
Risankizumab150 mg /Risankizumab 150 mg (Part B)92.7
Percentage of Participants Achieving a Static Physician Global Assessment (sPGA) Score of Clear or Almost Clear at Week 16 (Part A) Secondary · Week 16

The sPGA is an assessment by the investigator of the overall disease severity at the time of evaluation. Erythema (E), induration (I), and desquamation (D) are scored on a 5-point scale ranging from 0 (none) to 4 (severe). The sPGA ranges from 0 to 4, and is calculated as Clear (0) = 0 for all three; Almost clear (1) = mean \>0, \<1.5; Mild (2) = mean ≥1.5, \<2.5; Moderate (3) = mean ≥2.5, \<3.5; and Severe (4) = mean ≥3.5. Nonresponder imputation (NRI) was used for missing data.

GroupValue95% CI
Placebo (Part A)10.3
Risankizumab 75 mg (Part A)86.2
Risankizumab 150 mg (Part A)92.7
Percentage of Participants Achieving sPGA Score of Clear or Almost Clear at Week 52 (Part B) Secondary · Week 52

The sPGA is an assessment by the investigator of the overall disease severity at the time of evaluation. Erythema (E), induration (I), and desquamation (D) are scored on a 5-point scale ranging from 0 (none) to 4 (severe). The sPGA ranges from 0 to 4, and is calculated as Clear (0) = 0 for all three; Almost clear (1) = mean \>0, \<1.5; Mild (2) = mean ≥1.5, \<2.5; Moderate (3) = mean ≥2.5, \<3.5; and Severe (4) = mean ≥3.5. Nonresponder imputation (NRI) was used for missing data.

GroupValue95% CI
Placebo/Risankizumab 75 mg (Part B)96.3
Placebo/Risankizumab 150 mg (Part B)88.9
Risankizumab 75 mg/Risankizumab 75 mg (Part B)84.5
Risankizumab150 mg /Risankizumab 150 mg (Part B)94.5
Percentage of Participants Achieving 75% Improvement in PASI Score (PASI75) at Week 16 (Part A) Secondary · Week 16

PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign was assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis. PASI75 is defined as at least a 75% reduction in PASI score compared with the Baseline PASI score. The percent

GroupValue95% CI
Placebo (Part A)8.6
Risankizumab 75 mg (Part A)89.7
Risankizumab 150 mg (Part A)94.5
Percentage of Participants Achieving PASI75 at Week 52 (Part B) Secondary · Week 52

PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign was assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis. PASI75 is defined as at least a 75% reduction in PASI score compared with the Baseline PASI score. The percent

GroupValue95% CI
Placebo/Risankizumab 75 mg (Part B)100
Placebo/Risankizumab 150 mg (Part B)88.9
Risankizumab 75 mg/Risankizumab 75 mg (Part B)94.8
Risankizumab150 mg /Risankizumab 150 mg (Part B)96.4
Percentage of Participants Achieving 100% Improvement in PASI Score (PASI100) at Week 16 (Part A) Secondary · Week 16

PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign was assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis. PASI100 is defined as a 100% reduction in PASI score compared with the Baseline PASI score. The percent reducti

GroupValue95% CI
Placebo (Part A)0
Risankizumab 75 mg (Part A)22.4
Risankizumab 150 mg (Part A)32.7
Percentage of Participants Achieving PASI100 at Week 52 (Part B) Secondary · Week 52

PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign was assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis. PASI100 is defined as a 100% reduction in PASI score compared with the Baseline PASI score. The percent reducti

GroupValue95% CI
Placebo/Risankizumab 75 mg (Part B)40.7
Placebo/Risankizumab 150 mg (Part B)44.4
Risankizumab 75 mg/Risankizumab 75 mg (Part B)43.1
Risankizumab150 mg /Risankizumab 150 mg (Part B)41.8
Percentage of Participants (ITT Participants in Select Study Sites With Confirmed Diagnosis of Psoriatic Arthritis and Baseline Total Tender and Swollen Joint Count ≥ 3) Achieving an American College of Rheumatology 20 Response (ACR20) at Week 16 (Part A) Secondary · Week 16

Response defined by ACR20 criteria (improvement from baseline): ≥ 20% improvement in tender joint count; ≥ 20% improvement in swollen joint count; and ≥ 20% improvement in at least 3 of the 5 following parameters: Patient assessment of pain; Patient global assessment of disease activity; Investigator's global assessment of disease activity; Health Assessment Questionnaire Disability Index (HAQ-DI); and Acute phase reactant value (C-reactive protein). Nonresponder imputation (NRI) was used for missing data.

GroupValue95% CI
Placebo (Part A)0
Risankizumab 75 mg (Part A)40.0
Risankizumab 150 mg (Part A)33.3
Percentage of Participants (ITT Participants in Select Study Sites With Confirmed Diagnosis of Psoriatic Arthritis and Baseline Total Tender and Swollen Joint Count ≥ 3) Achieving an ACR20 at Week 52 (Part B) Secondary · Week 52

Response defined by ACR20 criteria (improvement from baseline): ≥ 20% improvement in tender joint count; ≥ 20% improvement in swollen joint count; and ≥ 20% improvement in at least 3 of the 5 following parameters: Patient assessment of pain; Patient global assessment of disease activity; Investigator's global assessment of disease activity; Health Assessment Questionnaire Disability Index (HAQ-DI); and Acute phase reactant value (C-reactive protein). Nonresponder imputation (NRI) was used for missing data.

GroupValue95% CI
Placebo/Risankizumab 75 mg (Part B)100
Placebo/Risankizumab 150 mg (Part B)100
Risankizumab 75 mg/Risankizumab 75 mg (Part B)60.0
Risankizumab150 mg /Risankizumab 150 mg (Part B)0

Adverse events — posted to ClinicalTrials.gov

Time frame: Treatment-emergent adverse events (TEAEs) and serious adverse events (TESAEs) were collected from first dose of study drug until 16 weeks after the last dose of study drug (up to 56 weeks).. Reporting threshold: 5%. Adverse-event reports describe events observed during the trial — not all are caused by the drug.

Placebo (Part A)
Serious: 1/58 (2%)
Deaths: 0/58
Risankizumab 75 mg (Part A)
Serious: 2/58 (3%)
Deaths: 0/58
Risankizumab 150 mg (Part A)
Serious: 2/55 (4%)
Deaths: 0/55
Placebo/Risankizumab 75 mg (Part B)
Serious: 2/27 (7%)
Deaths: 0/27
Placebo/Risankizumab 150 mg (Part B)
Serious: 0/27 (0%)
Deaths: 0/27
Risankizumab 75 mg/Risankizumab 75 mg (Part B)
Serious: 1/56 (2%)
Deaths: 0/56
Risankizumab 150 mg/Risankizumab 150 mg (Part B)
Serious: 1/54 (2%)
Deaths: 0/54

Serious adverse events (9 terms)

ReactionSystemPlacebo (Part A)Risankizumab 75 mg (Part A)Risankizumab 150 mg (Part A)Placebo/Risankizumab 75 mg…Placebo/Risankizumab 150 m…Risankizumab 75 mg/Risanki…Risankizumab 150 mg/Risank…
Acute myocardial infarctionCardiac disorders
Rectal polypGastrointestinal disorders
Pneumonia bacterialInfections and infestations
Rectal cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)
Loss of consciousnessNervous system disorders
Dermal cystSkin and subcutaneous tissue disorders
Erythrodermic psoriasisSkin and subcutaneous tissue disorders
PsoriasisSkin and subcutaneous tissue disorders
HypotensionVascular disorders
Other adverse events (16 terms — click to expand)

ReactionSystemPlacebo (Part A)Risankizumab 75 mg (Part A)Risankizumab 150 mg (Part A)Placebo/Risankizumab 75 mg…Placebo/Risankizumab 150 m…Risankizumab 75 mg/Risanki…Risankizumab 150 mg/Risank…
NasopharyngitisInfections and infestations
PsoriasisSkin and subcutaneous tissue disorders
Dental cariesGastrointestinal disorders
Hepatic function abnormalHepatobiliary disorders
InfluenzaInfections and infestations
PharyngitisInfections and infestations
Tinea pedisInfections and infestations
Blood triglycerides increasedInvestigations
Weight increasedInvestigations
Diabetes mellitusMetabolism and nutrition disorders
ArthralgiaMusculoskeletal and connective tissue disorders
VomitingGastrointestinal disorders
Oral herpesInfections and infestations
Back painMusculoskeletal and connective tissue disorders
AsthmaRespiratory, thoracic and mediastinal disorders
AsteatosisSkin and subcutaneous tissue disorders

Most-reported serious reactions: Acute myocardial infarction, Rectal polyp, Pneumonia bacterial, Rectal cancer, Loss of consciousness, Dermal cyst, Erythrodermic psoriasis, Psoriasis.

Data from ClinicalTrials.gov NCT03000075 adverse events section.

Sponsor's own description

This is a randomized double blind, double dummy, placebo controlled, parallel design study that is being performed to assess the safety and efficacy of BI 655066 (risankizumab).

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

  1. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
    Sbidian E, Chaimani A, Garcia-Doval I, Doney L, et al · · 2022 · cited 84× · PMID 35603936 · DOI 10.1002/14651858.cd011535.pub5
  2. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
    Sbidian E, Chaimani A, Afach S, Doney L, et al · · 2020 · cited 78× · PMID 31917873 · DOI 10.1002/14651858.cd011535.pub3
  3. Efficacy and safety of risankizumab in Japanese patients with moderate to severe plaque psoriasis: Results from the SustaIMM phase 2/3 trial.
    Ohtsuki M, Fujita H, Watanabe M, Suzaki K, et al · · 2019 · cited 69× · PMID 31237727 · DOI 10.1111/1346-8138.14941
  4. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
    Sbidian E, Chaimani A, Guelimi R, Garcia-Doval I, et al · · 2023 · cited 67× · PMID 37436070 · DOI 10.1002/14651858.cd011535.pub6
  5. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
    Sbidian E, Chaimani A, Garcia-Doval I, Doney L, et al · · 2021 · cited 54× · PMID 33871055 · DOI 10.1002/14651858.cd011535.pub4
  6. Risankizumab: Mechanism of action, clinical and translational science.
    Pang Y, D'Cunha R, Winzenborg I, Veldman G, et al · · 2024 · cited 26× · PMID 38266061 · DOI 10.1111/cts.13706
  7. Pharmacokinetics of Risankizumab in Asian Healthy Subjects and Patients With Moderate to Severe Plaque Psoriasis, Generalized Pustular Psoriasis, and Erythrodermic Psoriasis.
    Khatri A, Eckert D, Oberoi R, Suleiman A, et al · · 2019 · cited 23× · PMID 31257614 · DOI 10.1002/jcph.1473
  8. Impact of Pharmacokinetic and Pharmacodynamic Properties of Monoclonal Antibodies in the Management of Psoriasis.
    Rodríguez-Fernández K, Mangas-Sanjuán V, Merino-Sanjuán M, Martorell-Calatayud A, et al · · 2022 · cited 20× · PMID 35336028 · DOI 10.3390/pharmaceutics14030654

Verify or expand the search:

Other trials of risankizumab

Trials testing the same drug.

Other recruiting trials for Psoriasis

Currently open trials in the same condition.

Other AbbVie trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03000075.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing